PMID- 32488403
OWN - NLM
STAT- MEDLINE
DCOM- 20210129
LR  - 20210903
IS  - 1573-7233 (Electronic)
IS  - 0167-7659 (Print)
IS  - 0167-7659 (Linking)
VI  - 39
IP  - 3
DP  - 2020 Sep
TI  - Unraveling mucin domains in cancer and metastasis: when protectors become 
      predators.
PG  - 647-659
LID - 10.1007/s10555-020-09896-5 [doi]
AB  - A dynamic mucosal layer shields the epithelial cells lining the body cavities and 
      is made up of high molecular weight, heavily glycosylated, multidomain proteins 
      called mucins. Mucins, broadly grouped into transmembrane and secreted mucins, 
      are the first responders to any mechanical or chemical insult to the epithelia 
      and help maintain tissue homeostasis. However, their intrinsic properties to 
      protect and repair the epithelia are exploited during oncogenic processes, where 
      mucins are metamorphosed to aid the tumor cells in their malignant journey. 
      Diverse domains, like the variable number tandem repeats (VNTR), sea urchin sperm 
      protein enterokinase and agrin (SEA), adhesion-associated domain (AMOP), 
      nidogen-like domain (NIDO), epidermal growth factor-like domain (EGF), and von 
      Willebrand factor type D domain (vWD) on mucins, including MUC1, MUC4, MUC5AC, 
      MUC5B, and MUC16, have been shown to facilitate cell-to-cell and cell-to-matrix 
      interactions, and cell-autonomous signaling to promote tumorigenesis and distant 
      dissemination of tumor cells. Several obstacles have limited the study of mucins, 
      including technical difficulties in working with these huge glycoproteins, the 
      dearth of scientific tools, and lack of animal models; thus, the tissue-dependent 
      and domain-specific roles of mucins during mucosal protection, chronic 
      inflammation, tumorigenesis, and hematological dissemination of malignant cells 
      are still unclear. Future studies should try to integrate information on the 
      rheological, molecular, and biological characteristics of mucins to 
      comprehensively delineate their pathophysiological role and evaluate their 
      suitability as targets in future diagnostic and therapeutic strategies.
FAU - Ganguly, Koelina
AU  - Ganguly K
AD  - Department of Biochemistry and Molecular Biology, University of Nebraska Medical 
      Center, Omaha, NE, 68198, USA.
FAU - Rauth, Sanchita
AU  - Rauth S
AD  - Department of Biochemistry and Molecular Biology, University of Nebraska Medical 
      Center, Omaha, NE, 68198, USA.
FAU - Marimuthu, Saravanakumar
AU  - Marimuthu S
AD  - Department of Biochemistry and Molecular Biology, University of Nebraska Medical 
      Center, Omaha, NE, 68198, USA.
FAU - Kumar, Sushil
AU  - Kumar S
AD  - Department of Biochemistry and Molecular Biology, University of Nebraska Medical 
      Center, Omaha, NE, 68198, USA.
AD  - Fred and Pamela Buffet Cancer Center, University of Nebraska Medical Center, 
      Omaha, NE, 68198, USA.
FAU - Batra, Surinder K
AU  - Batra SK
AD  - Department of Biochemistry and Molecular Biology, University of Nebraska Medical 
      Center, Omaha, NE, 68198, USA. sbatra@unmc.edu.
AD  - Fred and Pamela Buffet Cancer Center, University of Nebraska Medical Center, 
      Omaha, NE, 68198, USA. sbatra@unmc.edu.
LA  - eng
GR  - R01 CA206444/CA/NCI NIH HHS/United States
GR  - U01 CA200466/CA/NCI NIH HHS/United States
GR  - R01 CA228524/CA/NCI NIH HHS/United States
GR  - R01 CA195586/CA/NCI NIH HHS/United States
GR  - U01 CA210240/CA/NCI NIH HHS/United States
GR  - P01 CA217798/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
PL  - Netherlands
TA  - Cancer Metastasis Rev
JT  - Cancer metastasis reviews
JID - 8605731
RN  - 0 (Mucins)
SB  - IM
MH  - Animals
MH  - Humans
MH  - Mucins/immunology/*metabolism
MH  - Neoplasm Metastasis
MH  - Neoplasms/immunology/*metabolism/pathology
MH  - Protein Domains
PMC - PMC7487023
MID - NIHMS1600294
OTO - NOTNLM
OT  - Cancer
OT  - Metastasis
OT  - Mucin domains
OT  - Mucins
OT  - Tumorigenesis
COIS- Diagnostics and Therapeutics, Inc. The other authors have no conflicts of 
      interest to declare. Conflicts of Interest: SKB is one of the co-founders of the 
      Sanguine Diagnostic and Therapeutics, Inc.
EDAT- 2020/06/04 06:00
MHDA- 2021/01/30 06:00
PMCR- 2021/09/01
CRDT- 2020/06/04 06:00
PHST- 2020/06/04 06:00 [pubmed]
PHST- 2021/01/30 06:00 [medline]
PHST- 2020/06/04 06:00 [entrez]
PHST- 2021/09/01 00:00 [pmc-release]
AID - 10.1007/s10555-020-09896-5 [pii]
AID - 10.1007/s10555-020-09896-5 [doi]
PST - ppublish
SO  - Cancer Metastasis Rev. 2020 Sep;39(3):647-659. doi: 10.1007/s10555-020-09896-5.